Slingshot Insights | Arwr Overview

ARWR Overview

Upcoming Projects (ARWR)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ARWR)

A Third Look: Discussing the investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), and their Phase 2b data presented at ACC 2024.
Ticker: ARWR
Executed On: Apr 23, 2024 at 05:30 PM EDT
A Second Look: Discussing the investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), and their Phase 2b data presented at ACC 2024.
Ticker: ARWR
Executed On: Apr 18, 2024 at 03:30 PM EDT
Discussing the investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), and their Phase 2b data presented at ACC 2024.
Ticker: ARWR
Executed On: Apr 18, 2024 at 12:00 PM EDT
A third look at an investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), for treatment of severe hypertriglyceridemia and mixed dyslipidemia.
Ticker: ARWR
Executed On: Jan 04, 2024 at 05:45 PM EST
A second look at an investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), for treatment of severe hypertriglyceridemia and mixed dyslipidemia.
Ticker: ARWR
Executed On: Dec 19, 2023 at 09:00 AM EST
A look at an investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), for treatment of severe hypertriglyceridemia and mixed dyslipidemia.
Ticker: ARWR
Executed On: Dec 13, 2023 at 12:30 PM EST
A Third Look: Discussing the potential of ARO-ANG3, an investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolemia.
Ticker: ARWR
Executed On: Jun 09, 2023 at 05:15 PM EDT
A Second Look: Discussing the potential of ARO-ANG3, an investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolemia.
Ticker: ARWR
Executed On: Jun 09, 2023 at 01:00 PM EDT
Discussing the potential of ARO-ANG3, an investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolemia.
Ticker: ARWR
Executed On: Jun 07, 2023 at 09:00 AM EDT
Delving into the phase 2 SEQUOIA trial data on Fazirsiran by Arrowhead Pharmaceuticals and its potential in A1AT liver disease
Ticker: ARWR
Executed On: Mar 28, 2023 at 05:00 PM EDT
A third look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, ARWR, NVS, IONS, REGN, SNY
Executed On: Aug 17, 2022 at 04:30 PM EDT

Upcoming & Overdue Catalysts (ARWR)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (ARWR)

Don’t see a strategic initiative related to the company you care about? Create your own!